Vascular dysfunction is a common finding in type 2 diabetes, although the response to urotensin II (UII), a potent vasoconstrictor peptide, remains unclear. We investigated whether a UII-induced contraction was increased in the aortas from type 2 diabetic Goto-Kakizaki (GK) rats at the chronic stage. At 36 or 37 weeks of age (older group), a UII-induced contraction was seen in GK rats and was reduced by a Rho kinase inhibitor or urotensin receptor (UT) antagonist, whereas UII failed to induce a contraction in aortas from age-matched Wistar rats. In UII-stimulated aortas, the expression of Rho kinases, Rho A, and phosphorylated myosin phosphatase target subunit 1 did not change between the two groups; however, phosphorylation of extracellular-regulated kinase 1/2 and p38 mitogen-activated protein kinase (MAPK) was greater in GK than in Wistar rats. Compared to intact aortas, UII-induced contractions were slightly, but not significantly, increased by endothelial denudation of the aortas of Wistar rats at 24 weeks of age. At 6 weeks of age (young group), the UII-induced contractions were seen in GK and Wistar groups. The total expression and the membrane-to-cytosol ratio of the UT protein slightly decreased in Wistar aortas with aging but not in GK aortas. These results demonstrate that the UII-induced contraction gradually decreased with aging in Wistar rats and was preserved in type 2 diabetes. Although alterations of UII-induced contractions during aging and type 2 diabetes may be associated with kinase activities (MAPKs or Rho kinase) or receptor profiles, further investigations are necessary to clarify the mechanisms.
Get full access to this article
View all access options for this article.
References
1.
ForbesJM, CooperME. Mechanisms of diabetic complications. Physiol Rev, 2013; 93:137–188.
2.
LaaksoM, KuusistoJ. Insulin resistance and hyperlycaemia in cardiovascular disease development. Nat Rev Endocrinol, 2014; 10:293–302.
3.
MatsumotoT, GoulopoulouS, TaguchiK, TostesRC, KobayashiT. Constrictor prostanoids and uridine adenosine tetraphosphate: Vascular mediators and therapeutic targets in hypertension and diabetes. Br J Pharmacol, 2015; 172:3980–4001.
4.
NunesKP, RigsbyCS, WebbRC. RhoA/Rho-kinase and vascular diseases: What is the link?. Cell Mol Life Sci, 2010; 67:3823–3836.
5.
PaneniF, BeckmanJA, CreagerMA, CosentinoF. Diabetes and vascular disease: Pathophysiology, clinical concequences, and medical therapy: Part I. Eur Heart J, 2013; 34:2436–2443.
6.
SowersJR. Diabetes mellitus and vascular disease. Hypertension, 2013; 61:943–947.
7.
GoulopoulouS, HannanJL, MatsumotoT, OgbiS, ErgulA, WebbRC. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes. Am J Physiol Heart Circ Physiol, 2015; 309:H297–H304.
8.
IshidaK, MatsumotoT, TaguchiK, KamataK, KobayashiT. Pravastatin normalizes endothelium-derived contracting factor-mediated response via suppression of Rho-kinase signaling in mesenteric artery from aged type 2 diabetic rat. Acta Physiol, 2012a;205:255–265.
9.
IshidaK, MatsumotoT, TaguchiK, KamataK, KobayashiT. Protein kinase C delta contributes to increase in EP3 agonist-induced contraction in mesenteric arteries from type 2 diabetic Goto-Kakizaki rats. Pflugers Arch, 2012b;463:593–602.
10.
KobayashiT, NemotoS, IshidaK, TaguchiK, MatsumotoT, KamataK. Involvement of CaM kinase II in the impairment of endothelial function and eNOS activity in aortas of Type 2 diabetic rats. Clin Sci, 2012; 123:375–386.
11.
MatsumotoT, IshidaK, NakayamaN, KobayashiT, KamataK. Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. Am J Physiol Heart Circ Physiol, 2009; 296:H1388–H1397.
12.
MatsumotoT, KobayashiT, IshidaK, TaguchiK, KamataK. Enhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetes. Br J Pharmacol, 2010; 160:1092–1104.
13.
MatsumotoT, WatanabeS, KawamuraR, TaguchiK, KobayashiT. Enhanced uridine adenosine tetraphosphate-induced contraction in renal artery from type 2 diabetic Goto-Kakizaki rats due to activated cyclooxygenase/thromboxane receptor axis. Pflugers Arch, 2014a;466:331–342.
14.
MatsumotoT, WatanabeS, TaguchiK, KobayashiT. Mechanisms underlying increased serotonin-induced contraction in carotid arteries from chronic type 2 diabetic Goto-Kakizaki rats. Pharmacol Res, 2014b;87:123–132.
15.
MatsumotoT, WatanabeS, AndoM, YamadaK, IguchiM, TaguchiK, KobayashiT. Diabetes and age-related differences in vascular function of renal artery: Possible involvement of endoplasmic reticulum stress. Rejuvenation Res, 2016; 19:41–52.
16.
TaguchiK, MatsumotoT, KamataK, KobayashiT. G protein-coupled receptor kinase 2, with β-arrestin 2, impairs insulin-induced Akt/endothelial nitric oxide synthase signaling in ob/ob mouse aorta. Diabetes, 2012a;61:1978–1985.
17.
TaguchiK, MorishigeA, MatsumotoT, KamataK, KobayashiT. Enhanced estradiol-induced vasorelaxation in aortas from type 2 diabetic mice may reflect a compensatory role of p38 MAPK-mediated eNOS activation. Pflugers Arch, 2012b;464:205–215.
18.
DonathMY. Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Diabetologia, 2016; 59:679–682.
19.
TurnerN, ZengXY, OsborneB, RogersS, YeJM. Repurposing drugs to target the diabetes epidemic. Trends Pharmacol Sci, 2016; 37:379–389.
20.
Carrillo-SepulvedaMA, MatsumotoT, NunesKP, WebbRC. Therapeutic implications of peptide interactions with G-protein-coupled receptors in diabetic vasculopathy. Acta Physiol, 2014; 211:20–35.
21.
ErgulA. Endothelin-1 and diabetic complications: Focus on the vasculature. Pharmacol Res, 2011; 63:477–482.
22.
OnanD, HannanRD, ThomasWG. Urotensin II: The old kid in town. Trends Endocrinol Metab, 2004; 15:175–182.
23.
RichardsAM, CharlesC. Urotensin II in the cardiovascular system. Peptides, 2004; 25:1795–1802.
24.
RossB, McKendyK, GiaidA. Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol, 2010; 298:R1156–R1172.
25.
RussellFD. Urotensin II in cardiovascular regulation. Vasc Health Risk Manag, 2008; 4:775–785.
26.
VaudryH, LeprinceJ, ChatenetD, FournierA, LambertDG, Le MevelJC, OhisteinEH, SchiwertaniA, TostivintH, VaudryD. International union of basic and clinical pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: From structure to function. Pharmacol Rev, 2015; 67:214–258.
27.
ZhuYC, ZhuYZ, MoorePK. The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol, 2006; 148:884–901.
28.
IglewskiM, GrantSR. Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells. Vasc Health Risk Manag, 2010; 6:723–734.
29.
MatsusakaS, WakabayashiI. Enhancement of vascular smooth muscle cell migration by urotensin II. Naunyn Schmiedebergs Arch Pharmacol, 2006; 373:381–386.
TasakiK, HoriM, OzakiH, KarakiH, WakabayashiI. Mechanism of human urotensin II-induced contraction in rat aorta. J Pharmacol Sci, 2004; 94:376–383.
32.
AmesRS, SarauHM, ChambersJK, WilletteRN, AiyarNV, RomanicAM, LoudenCS, FoleyJJ, SauermelchCF, CoatneyRW, AoZ, DisaJ, HolmesSD, StadelJM, MartinJD, LiuWS, GloverGI, WilsonS, McNultyDE, EllisCE, ElshourbagyNA, ShabonU, TrillJJ, HayDW, OhlsteinEH, BergsmaDJ, DouglasSA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 1999; 401:282–286.
33.
Dominguez-RodriguezA, DiazI, Rodriguez-MoyanoM, Calderon-SanchezE, RosadoJA, OrdonezA, SmaniT. Urotensin-II signaling mechanism in rat coronary artery: Role of STIM1 and Orai1-dependent store operated calcium influx in vasoconstriction. Arterioscler Thromb Vasc Biol, 2012; 32:1325–1332.
34.
RossowskiWJ, ChenBL, TaylorJE, DattaR, CoyDH. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: Inhibition by somatostatin receptor antagonists. Eur J Pharmacol, 2002; 438:159–170.
35.
WangYX, DingYJ, ZhuYZ, ShiY, YaoT, ZhuYC. Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. Am J Physiol Heart Circ Physiol, 2007; 292:H348–H359.
36.
WatanabeT, PakalaR, KatagiriT, BenedictCR. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation, 2001; 104:16–18.
37.
GrusonD, RousseauMF, KetelslegersJM, HermansMP. Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype. J Clin Hypertens, 2010; 12:653–660.
38.
SuguroT, WatanabeT, KodateS, XuG, HiranoT, AdachiM, MiyazakiA. Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. Clin Sci, 2008; 115:327–334.
39.
TaburS, KorkmazH, ErenMA, OguzE, SabuncuT, AksoyN. Urotensin-II level and its association with oxidative stress in early diabetic nephropathy. J Diabetes Complications, 2015; 29:115–119.
40.
TotsuneK, TakahashiK, AriharaZ, SoneM, MurakamiO, ItoS, KikuyaM, OhkuboT, HashimotoJ, ImaiY. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: Association with progress of diabetic nephropathy. Peptides, 2004; 25:1809–1814.
41.
WangHX, ZengXJ, LiuY, WangJ, LuIQ, HaoG, ZhangLK, TangCS. Elevated expression of urotensin II and its receptor in skeletal muscle of diabetic mouse. Regul Pept, 2009; 154:85–90.
42.
YoshimotoT, MatsushitaM, HirataY. Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor. Peptides, 2004; 25:1775–1781.
43.
KingAJ. The use of animal models in diabetes research. Br J Pharmacol, 2010; 166:877–894.
GotoY, KakizakiM, MasakiN. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med, 1976; 119:85–90.
46.
PorthaB, SerradasP, BailbeD, SuzukiK, GotoY, GiroixMH. Beta-cell insensitivity to glucose in the GK rat, a spontaneous nonobese model for type II diabetes. Diabetes, 1991; 40:486–491.
47.
KobayashiT, MatsumotoT, OoishiK, KamataK. Differential expression of alpha2D-adrenoceptor and eNOS in aortas from early and later stages of diabetes in Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol, 2004; 287:H135–H143.
48.
NemotoS, MatsumotoT, TaguchiK, KobayashiT. Relationships among protein tyrosine phosphatasae 1B, angiotensin II, and insulin-mediated aortic responses in type 2 diabetic Goto-Kakizaki rats. Atherosclerosis, 2014; 233:64–71.
49.
AbdelsaidM, KaczmarekJ, CouchaM, ErgulA. Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: Relevance to glycemic control. Life Sci, 2014; 233:64–71.
50.
AllahdadiKJ, HannanJL, ErgulA, TostesRC, WebbRC. Internal pudendal artery from type 2 diabetic female rats demonstrate elevated endothelin-1-mediated contstriction. J Sex Med, 2011; 8:2472–2483.
51.
Carrillo-SepulvedaMA, MatsumotoT. Phenotypic modulation of mesenteric vascular smooth muscle cells from type 2 diabetic rats is associated with decreased caveolin-1 expression. Cell Physiol Biochem, 2014; 34:1497–1506.
52.
TagashiraH, MatsumotoT, TaguchiK, ZhangC, HanF, IshidaK, NemotoS, KobayashiT, FukunagaK. Vascular endothelial σ1-receptor stimulation with SA4503 rescues aortic relaxation via Akt/eNOS signaling in ovariectomized rats with aortic banding. Circ J, 2013; 77:2831–2840.
53.
WatanabeS, MatsumotoT, AndoM, AdachiT, KobayashiS, IguchiM, TakeuchiM, TaguchiK, KobayashiT. Multiple activation mechanisms of serotonin-mediated contraction in the carotid arteries obtained from spontaneously hypertensive rats. Pflugers Arch, 2016; 468:1271–1282.
54.
WatanabeS, MatsumotoT, OdaM, YamadaK, TakagiJ, TaguchiK, KobayashiT. Insulin augments serotonin-induced contraction via activation of the IR/PI3K/PDK1 pathway in the rat carotid artery. Pflugers Arch, 2016; 468:667–677.
55.
GoulopoulouS, WebbRC. Symphony of vascular contraction: How smooth muscle lose harmony to signal increased vascular resistance in hypertension. Hypertension, 2014; 63:e33–e39.
56.
KitazawaT, KitazawaK. Size-dependent heterogeneity of contractile Ca2+ sensitization in rat arterial smooth muscle. J Physiol, 2012; 590:5401–5423.
57.
IshihataA, SakaiM, KatanoY. Vascular contractile effect of urotensin II in young and aged rats: Influence of aging and contribution of endothelial nitric oxide. Peptides, 2006; 27:80–86.
58.
MaguireJJ, KucRE, DavenportAP. Orphan-receptor ligand human urotensin II: Receptor locarization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol, 2000; 131:441–446.
59.
GiebingG, TolleM, JurgensenJ, EichhorstJ, FurkertJ, BeyemannM, Neuschafer-RubeF, RosenthalW, ZidekW, van der GietM, OkscheA. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ Res, 2005; 97:707–715.
60.
DongX, YeX, SongN, ZhaoJ, DiB, PengF, TangC, DingW. Urotensin II promotes the production of LTC4 in rat aortic adventitial fibroblasts through NF-κB-5-LO pathway by p38 MAPK and ERK activations. Heart Vessels, 2013; 28:514–523.
61.
LinY, MatsumuraK, TsuchihashiT, FukuharaM, FujiiK, IidaM. Role of ERK and Rho kinase pathways in central pressor action of urotensin II. J Hypertens, 2004; 22:983–988.
62.
UsuiT, OkadaM, HaraY, YamawakiH. Death-associated protein kinase 3 mediates vascular inflammation and development of hypertension in spontaneously hypertensive rats. Hypertension, 2012; 60:1031–1039.
63.
GouldPS, GuM, LiaoJ, AhmadS, CudmoreMJ, AhmedA, VatishM. Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia. Hypertension, 2010; 56:172–178.
64.
LimM, HonisettS, SparkesCD, KomesaroffP, KompaA, KrumH. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation, 2004; 109:1212–1214.
65.
OngKL, LamKS, CheungBM. Urotensin II: Its function in health and its role in disease. Cardiovasc Drug Ther, 2005; 19:65–75.
66.
NothackerHP, WangZ, McNeillAM, SaitoY, MertenS, O'DowdB, DucklesSP, CivelliO. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol, 1999; 1:383–385.
67.
ItohH, McMasterD, LederisK. Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur J Pharmacol, 1988; 149:61–66.
68.
XieN, LiuL. Elevated expression of urotensin II and its receptor in great artery of type 2 diabetes and its significance. Biomed Pharmacother, 2009; 63:731–741.
69.
AlbaneseI, DaskalopoulouSS, YuB, YouZ, GenestJ, Alsheikh-AliA, SchwertaniAG. The urotensin II system and carotid atherosclerosis: A role in vascular calcification. Front Pharmacol, 2016; 7:149.
70.
BousetteN, HuF, OhlsteinEH, DhanakD, DouglasSA, GiaidA. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol, 2006; 41:285–295.
71.
PrinsterSC, HagueC, HallRA. Heterodimerization of g protein-coupled receptors: Specificity and functional significance. Pharmacol Rev, 2005; 57:289–298.
72.
SauzeauV, Le MellionnecE, BertoglioJ, ScalbertE, PacaudP, LoirandG. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. 2001; Circ Res, 88:1102–1104.
73.
ShimokawaH, SunamuraS, SatohK. RhoA/Rho kinase in the Cardiovascular System. Circ Res, 2016; 118:352–366.
74.
CamardaV, RizziA, CaloG, GendronG, PerroniSI, KostenisE, ZamboniP, MascoliF, RegoliD. Effects of human urotensin II in isolated vessels of various species: Comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol, 2002; 365:141–149.
75.
BrailoiuE, JiangX, BrailoiuGC, YangJ, ChangJK, WangH, DunNJ. State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells. Peptides, 2008; 29:721–726.
76.
YanoK, HicksJW, VaudryH, ConlonJM. Cardiovascular actions of frog urotensin II in the frog. Rana catesbeiana. Gen Comp Endocrinol, 1995; 97:103–110.
77.
LecointreC, DesruesL, JoubertJE, PerzoN, GuichetPO, Le JoncourV, BruleC, ChabbertM, LeducR, PrezeauL, LaquerriereA, ProustF, GandolfoP, MorinF, CastelH. Signaling switch of the urotensin II vasoactive peptide GPCR: Prototypic chemotaxic mechanism in glioma. Oncogene, 2015; 34:5080–5094.
78.
WatsonAM, OlukmanM, KoulisC, TuY, SamijonoD, YuenD, LeeC, BehmDJ, CooperME, Jandeleit-DahmKA, CalkinAC, AllenTJ. Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: Studies in humans and in a mouse model of diabetes. Diabetologia, 2013; 56:1155–1165.
79.
ClozelM, HessP, QiuC, DingSS, ReyM. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther, 2014; 316:1115–1121.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
